Barclays
AVTX icon

Barclays’s Avalo Therapeutics AVTX Stock Holding History

Barclays’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$219K Sell
14,642
-91,172
-86% -$1.43M ﹤0.01% 3640
2025
Q4 		$1.92M Buy
105,814
+96,468
+1,032% +$1.63M ﹤0.01% 2961
2025
Q3 		$119K Buy
+9,346
New +$80.4K ﹤0.01% 4562
2022
Q3 		– Hold
0
– – – 4780
2022
Q2 		– Sell
-4
Closed -$5.35K – 5016
2022
Q1 		$7K Buy
+4
New +$10K ﹤0.01% 4648
2021
Q3 		– Sell
-2
Closed -$22K – 4738
2021
Q2 		$22K Sell
2
-10
-83% -$83.8K ﹤0.01% 4455
2021
Q1 		$108K Buy
12
+8
+200% +$75.6K ﹤0.01% 3967
2020
Q4 		$31K Sell
4
-2
-33% -$13.9K ﹤0.01% 4577
2020
Q3 		$37K Hold
6
– – ﹤0.01% 4727
2020
Q2 		$41K Buy
6
+3
+100% +$21.8K ﹤0.01% 5009
2020
Q1 		$18K Sell
3
-5
-63% -$52.9K ﹤0.01% 5666
2019
Q4 		$119K Buy
8
+4
+100% +$42.2K ﹤0.01% 5376
2019
Q3 		$36K Sell
4
-1
-20% -$11.2K ﹤0.01% 6038
2019
Q2 		$75K Sell
5
-14
-74% -$212K ﹤0.01% 5882
2019
Q1 		$319K Buy
+19
New +$284K ﹤0.01% 4477
2018
Q3 		– Sell
-3
Closed -$42K – 7107
2018
Q2 		$42K Buy
+3
New +$35.7K ﹤0.01% 5737
2018
Q1 		– Hold
0
– – – 7044

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Barclays's AVTX Position: Q1 2026 in Review

Barclays reduced its Avalo Therapeutics (AVTX) stake by 86% in Q1 2026, selling an estimated $1.43M and leaving 14,642 shares worth $219K. The position accounts for ﹤0.01% of the portfolio, ranked #3640.

Barclays first reported a position in AVTX in Q2 2018 and has held it in 15 quarters since. The position peaked at $1.92M in Q4 2025. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Barclays held 14,642 shares of Avalo Therapeutics worth $219K as of Q1 2026.
  • Barclays sold 91,172 Avalo Therapeutics shares in Q1 2026, an estimated $1.43M.
  • Avalo Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3640 holding.
  • Barclays first reported a position in Avalo Therapeutics in Q2 2018 and has held it in 15 quarters since.
  • Barclays's Avalo Therapeutics position peaked at $1.92M in Q4 2025.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.